The Group has obtained the following awards:

Asia’s 200 Best Under a Billion Companies
For the third consecutive year, the Group has been ranked by Forbes in October 2013 as one of Asia’s 200 Best Under a Billion Companies. This award is a recognition and appreciation of the ongoing dedication and contribution made by management and staff of the Group.

2012 Hong Kong Awards for Industries: Technology Achievement Award
The Group wins the 2012 Hong Kong Awards for Industries: Technology Achievement Award in respect of its first-in-class anti-platelet drug Declotana® (Anfibatide). As a first-in-class drug, Declotana® is the first platelet Ib antagonist to complete human phase I study and to start Phase II study. Declotana® represents a novel therapeutic mechanism and may advance the treatment of acute coronary syndrome and percutaneous coronary intervention.

Asia's 200 Best Under A Billion Company
In September 2011, Lee's Pharmaceutical Holdings Limited has been selected by Forbes as one of Asia's 200 Best Under A Billion Company (turnover less than US$1 billion).

Hong Kong Outstanding Enterprises 2010
On 6 December 2010, Lee’s Pharmaceutical Holdings Limited has been accredited “Hong Kong Outstanding Enterprises 2010” by financial magazine Economic Digest.

Best Small-cap Company
In May 2010, FinanceAsia announced that Lee’s Pharmaceutical Holdings Limited won the 2010 Best Small-cap Company (Ranked 2nd) in China. This is the result of annual poll made by FinanceAsia from more than 300 investors and analyst across the region.

Superb Enterprise
In March 2008, Zhaoke was accredited as “Superb Enterprise” by the Food and Drug Administration of the Anhui Province to recognize its high quality in management and high efficiency in the production of drugs.

High-tech Enterprise
In December 2007, Zhaoke was accredited as High Technology Enterprise by the Science and Technology Bureau of the Anhui Province.

2001 Hong Kong Innovation and Technology Fund Matching Grant

In May 2001, the Group has been awarded a matching grant by the Hong Kong Government's Innovation and Technology Fund for the Group's project “Screening of Human Heparanase Inhibitors as Anti Cancer Drugs from Traditional Chinese Medicine” which is in cooperation with the Biological Research Institute of the Hong Kong University of Science and Technology.

Key National Technology and Innovation Project for the year 1999
In June 1999, Declotana, a new product of the Group under research and development, was approved as Key National Technology and Innovation Project for the year 1999 by State Economic and Trade Commission of the PRC.

Foreign Investment Advanced Technology Enterprise
In April 1999, Zhaoke was accredited as Foreign Investment Advanced Technology Enterprise by the Ministry of Foreign Trade and Economic Cooperation of the PRC.

National Torch Project
In March 1996, Zhaoke was accredited by Ministry of Science and Technology, to undertake a national project of National Torch Project for the development and commercialization of Defibrase.

High-tech Enterprise
In September 1995, Zhaoke was accredited as New High Technology Enterprise by Anhui Province Science and Technology Committee.

Second Prize in Natural Science
In November 1994, study of enzyme from snake venom of Agkistrodon Acutus undertaken by Zhaoke was accredited Second Prize in Natural Science by Chinese Academy of Science.

 

© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD